The aim of quality assurance of a drug product is to ensure that the drug provided to the patient is safe, efficacious and of good quality. The process of quality assurance begins from the manufacturer and continues to the point of administration of the drug to the patient. Compliance with Good Manufacturing Practices (GMP) is an important component of quality assurance.
Therefore, government shall take appropriate action to ensure that:
i. Regulatory authorities are strengthened and empowered to monitor and enforce effective compliance with quality assurance provisions by manufacturers of imported and locally produced drugs to ensure that patients and consumers receive only safe, efficacious and good quality drugs;
ii. Drug imports and purchases at all levels in public and private health facilities shall meet the standards of good quality and safety before such drugs are distributed to dispensing units;
iii. Good Manufacturing Practices [GMP] shall continue to be monitored and enforced in all drug manufacturing outfits in the country;
iv. Duly qualified individuals and organisations shall be licensed to set up quality control laboratories for assessing the quality of drugs in the national drug distribution system;
v. University departments with appropriate personnel and equipment will be encouraged to assess drug quality to complement the functions of the laboratories of the regulatory authorities;
vi. Adequately equipped and staffed drug quality control laboratories will be established in strategic locations within the various geo-political zones of the country; and
vii. Manufacturers will be required to package their products in appropriate containers in order to ensure the quality and stability of such products.